1. Home
  2. ANNX vs TBLA Comparison

ANNX vs TBLA Comparison

Compare ANNX & TBLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.04

Market Cap

812.7M

Sector

Health Care

ML Signal

HOLD

Logo Taboola.com Ltd.

TBLA

Taboola.com Ltd.

HOLD

Current Price

$4.92

Market Cap

952.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANNX
TBLA
Founded
2011
2007
Country
United States
United States
Employees
93
2000
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
812.7M
952.2M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ANNX
TBLA
Price
$5.04
$4.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
4
Target Price
$16.50
$5.00
AVG Volume (30 Days)
1.9M
2.8M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$7.63
Revenue Next Year
$16,320.74
$5.25
P/E Ratio
N/A
$42.36
Revenue Growth
N/A
N/A
52 Week Low
$1.85
$2.84
52 Week High
$7.18
$5.26

Technical Indicators

Market Signals
Indicator
ANNX
TBLA
Relative Strength Index (RSI) 34.74 68.77
Support Level $4.79 $3.86
Resistance Level $5.07 $5.26
Average True Range (ATR) 0.28 0.25
MACD -0.09 0.02
Stochastic Oscillator 16.39 77.45

Price Performance

Historical Comparison
ANNX
TBLA

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About TBLA Taboola.com Ltd.

Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.

Share on Social Networks: